Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Hansen, B
Additionally, this rate of study drug discontinuation was numerically lower compared to rates in prior studies of dual RAAS inhibition (ALTITUDE 4.8% and VA-NEPHRON-D 9.9%)
PubMed , Acta Neuropsychiatrica , vol
Trials like EMPAREG OUTCOME and REWIND underscore how newer medications reshape risk management, leading some experts to recommend earlier initiation of these agents in patients with elevated cardiovascular or renal risks
US$ 25.71
US$ 22.84
US$ 23.81
US$ 28.67
US$ 25.38
US$ 23.64
